Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.40% | 35.08% | 27.42% | -11.54% | -53.25% |
| Total Depreciation and Amortization | 25.00% | -89.09% | 50.00% | 0.00% | -20.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.42% | -54.01% | -57.40% | 57.85% | 207.05% |
| Change in Net Operating Assets | 761.16% | 44.13% | -91.22% | -54.96% | -92.78% |
| Cash from Operations | 26.19% | 35.42% | -43.52% | -7.09% | -97.87% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.08% | -33.52% | -11.74% | -58.19% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3,585.40% | 24.97% | -109.60% | 66.98% | -- |
| Cash from Financing | 83.40% | -33.88% | -63.53% | -57.56% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.53% | 36.62% | -97.39% | -154.06% | -15.44% |